Novel target for anti-cancer and immune-enhancing
AssigneeGenome and Company
InventorsBu-Nam JEON, Yun Yeon KIM, Suro LEE, Youn Kyung HOUH, Joo-Yeon CHUNG, Areum JEONG, Mi Young CHA
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL3, CNTN4 and/or CD351, and a method of providing information necessary for analysis of cancer prognosis using KIRREL3, CNTN4 and/or CD351.
Claims20
A method of treating or preventing cancer, comprising administering one or more inhibitors of KIRREL3, CNTN4 and CD351 to a subject in need thereof.
A method of immune-enhancing, comprising administering one or more inhibitors of KIRREL3, CNTN4 and CD351 to a subject in need thereof.
A method of screening an anti-cancer agent comprising:
- (a) treating a cancer cell with a candidate anti-cancer agent;
- and
- (b) measuring expression or activity of one or more of KIRREL3, CNTN4 and CD351 in the cancer cell.
An anti-CNTN4 antibody or antigen-binding fragment thereof, wherein when bound to CNTN4, the anti-CNTN4 antibody or antigen-binding fragment thereof binds to Fibronectin 2 domain of CNTN4.
A method of screening an anti-cancer agent comprising:
- (a) treating a cancer cell with a candidate anti-cancer agent;
- and
- (b) measuring a binding of amyloid precursor protein (APP) to CNTN4.
Dependencies are inferred from the claim text.